Deutsche Bank
INFI

Deutsche Bank’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Deutsche Bank’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-856
Closed -$10K – 6140
2014
Q2 		$10K Buy
+856
New +$8.92K ﹤0.01% 5509

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Deutsche Bank's INFI Position: Q2 2022 in Review

Deutsche Bank sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2022, closing a stake of 52,999 shares — an estimated $60K sold.

Deutsche Bank first reported a position in INFI in Q2 2013 and held it in 25 quarters. The position peaked at $9.39M in Q4 2013. 77 funds tracked by Wall St. Rank hold INFI as of Q2 2022.

  • Deutsche Bank reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 52,999 Infinity Pharmaceuticals, Inc. shares in Q2 2022, an estimated $60K.
  • Deutsche Bank first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
  • Deutsche Bank's Infinity Pharmaceuticals, Inc. position peaked at $9.39M in Q4 2013.
  • 77 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.